TABLE 2.
Baseline Characteristics of 87 Patients with MBC
| Characteristic | Data |
|---|---|
| Age at diagnosis of MBC (y) | 72.7 (41.1–89.4) |
| Time from primary breast cancer to MBC (y) | 5.13 (0.00–38.1) |
| MBC diagnosis | |
| De novo MBC | 27 (31.0%) |
| First distant relapse of MBC | 60 (69.0) |
| ER status* | |
| Negative, 0% | 12 (13.8) |
| Positive, 1%–100% | 75 (86.2) |
| HER2 status* | |
| Normal | 80 (92.0) |
| Positive | 5 (5.75) |
| Unknown | 2 (2.30) |
| Molecular subtype* | |
| ER+/HER2− | 71 (81.6) |
| ER+/HER2 unknown | 2 (2.30) |
| HER2+ (ER±) | 5 (5.75) |
| Triple-negative | 9 (10.3) |
| First-line treatment | |
| Endocrine therapy† | 10 (11.5) |
| Endocrine therapy† + cyclin-dependent kinase 4/6‡ | 60 (69.0) |
| Chemotherapy§ | 12 (13.8) |
| Chemotherapy§ + trastuzumab + pertuzumab | 4 (4.60) |
| Chemotherapy + pembrolizumab | 1 (1.15) |
| Number of metastases∥ | |
| 1 | 1 (1.15) |
| 2–4 | 7 (8.05) |
| ≥5 | 79 (90.8) |
| Organs involved∥ | |
| Bone only¶ | 23 (26.4) |
| Lymph node only | 4 (4.60) |
| Visceral involvement | 22 (25.3) |
| Mixed (not visceral)# | 38 (43.7) |
*
Biomarker profile of metastatic lesion or concurrent local recurrence.
†
Aromatase inhibitor or fulvestrant.
‡
Palbociclib, ribociclib, or abemaciclib.
§
Epirubicin, cyclophosphamide, taxanes, carboplatin, gemcitabine, vinorelbine, or capecitabine.
∥
Combined CE-CT and 18F-FDG PET/CT assessment.
¶
Bone-only metastasis ± breast ± axillary lymph nodes.
#
Mixed bone, lymph node, lung, skin, or other metastases.
ER = estrogen receptor; HER2 = human epidermal growth receptor 2. Qualitative data are number and percentage; continuous data are median and range.